Stockscreener 앱 받기
84.10
0.02%
-0.08
전일 마감가:
$84.18
열려 있는:
$84.2
하루 거래량:
1.05M
Relative Volume:
0.08
시가총액:
$210.06B
수익:
$63.43B
순이익/손실:
$16.42B
주가수익비율:
12.96
EPS:
6.49
순현금흐름:
$14.72B
1주 성능:
+1.14%
1개월 성능:
+5.38%
6개월 성능:
-9.08%
1년 성능:
-27.32%
1일 변동 폭
$83.30
$84.41
1주일 범위
$83.28
$85.81
52주 변동 폭
$73.31
$120.30
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
84.10 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
740.80 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.25 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
213.28 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.84 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Veterinary Oncology Market Shares, Competition and Trends Analysis 2025-2030: Discover the Impact of Advanced Therapies and Digital Tools - GlobeNewswire Inc.
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Merck's cholesterol drug gets a boost with another late-stage trial success - Reuters
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK) - Benzinga
Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds - Morningstar
Leerink Partners Remains Bullish on Merck & Co. (MRK) - MSN
No Spoils For VICTOR As Bayer/Merck & Co’s Verquvo Fails Phase III Trial - insights.citeline.com
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - PharmiWeb.com
Merck succeeds in late-stage trial for cholesterol drug - Seeking Alpha
First-Ever Oral PCSK9 Drug Success: Merck's Enlicitide Shows Breakthrough in Cholesterol Treatment - Stock Titan
Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028 - Yahoo Finance
Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug - MSN
Animal Health Market Trends, Key Player Strategies, and Growth Outlook to 2034 - GlobeNewswire Inc.
Co. Inc.Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial - Yahoo Finance
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction - FinancialContent
Is Merck Stock Outperforming the Dow? - MSN
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Merck to Participate in the 2025 Wells Fargo Healthcare Conference - PharmiWeb.com
2025 Wells Fargo Healthcare Conference - Merck.com
Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances - Insider Monkey
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% in Q2 2025 - AInvest
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% - Yahoo Finance
Summit, Akeso Lung Cancer Drug Rivals Merck’s KeytrudaSummit Therapeutics (NASDAQ:SMMT) - Benzinga
Rising as One, Shining as Many - GlobeNewswire Inc.
Merck & Co., Inc. shares fall 1.73% intraday after Bernstein reiterates Neutral rating, lowering target price to EUR 138. - AInvest
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 - The Globe and Mail
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck shares snapped six-session winning streak (NYSE:MRK) - Seeking Alpha
Merck & Co Inc (MRK) Highlights Gaps in Flea and Tick Prevention Adherence - AInvest
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds - Business Wire
Merck & Co., Inc. shares rise 1.71% intraday after FDA grants Breakthrough Therapy Designation to Ifinatamab Deruxtecan for small cell lung cancer. - AInvest
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Stock: Buy The Weakness (NYSE:MRK) - Seeking Alpha
Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics - insights.citeline.com
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness - MSN
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey - Yahoo Finance
Top Analyst Reports for Merck, Palo Alto & Freeport - Yahoo Finance
10 Stocks Jim Cramer Discussed As He Questioned Official Data - Insider Monkey
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
0.51%
자본화:
|
볼륨(24시간):